A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
Multicenter, open-label, phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in
subjects with Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple
Myeloma.
Phase:
Phase 1
Details
Lead Sponsor:
Trillium Therapeutics Inc.
Treatments:
Azacitidine Dexamethasone Immunoglobulin G Proteasome Inhibitors Rituximab Venetoclax